Mounjaro, Wegovy, Trulicity: GLP-1 Lawsuits Beyond Ozempic

When people hear “Ozempic lawsuit,” they often assume the litigation is limited to a single drug. In reality, the GLP-1 receptor agonist litigation — consolidated in MDL 3094 — encompasses an entire class of medications manufactured by multiple pharmaceutical companies. If you took Mounjaro, Wegovy, Trulicity, Saxenda, or Rybelsus and suffered serious side effects, your legal options may be identical to those of Ozempic users.

Here is what you need to know about each drug, its manufacturer, the injuries associated with it, and the current state of litigation.

Mounjaro (Tirzepatide) — Eli Lilly

What It Is

Mounjaro is manufactured by Eli Lilly and Company and was approved by the FDA in 2022 for type 2 diabetes. It contains tirzepatide, a dual GIP/GLP-1 receptor agonist — meaning it activates two different incretin receptors rather than just one. In 2023, it was also approved under the brand name Zepbound for chronic weight management.

How It Differs from Ozempic

While Ozempic targets only the GLP-1 receptor, Mounjaro targets both GLP-1 and GIP receptors. This dual mechanism has produced impressive results for blood sugar control and weight loss in clinical trials, but it also means the drug has a potent effect on gastric emptying — the same mechanism that drives gastroparesis risk.

Associated Injuries

• Gastroparesis — delayed gastric emptying, confirmed by gastric emptying study
• Bowel obstruction — intestinal blockage requiring emergency medical treatment or surgery
• Gallbladder disease — gallstones, cholecystitis, and cholecystectomy
• Pancreatitis — inflammation of the pancreas
• Severe nausea and vomiting — beyond typical side effects, reaching the level of cyclic vomiting syndrome requiring medical intervention

Litigation Status

Mounjaro/tirzepatide cases are included in the MDL 3094 proceedings alongside semaglutide-based claims. Eli Lilly is a named defendant. The case count for Mounjaro-specific claims has been growing as the drug’s market share has increased rapidly since its approval.

Wegovy (Semaglutide) — Novo Nordisk

What It Is

Wegovy is manufactured by Novo Nordisk and was approved by the FDA in 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It contains the same active ingredient as Ozempic — semaglutide — but at a higher dose (2.4 mg weekly vs. Ozempic’s maximum of 2.0 mg).

Key Distinction

Because Wegovy is prescribed for weight loss rather than diabetes, many of its users are otherwise healthy individuals who were not managing a chronic disease. This population may have different expectations about risk tolerance compared to patients managing type 2 diabetes, and plaintiffs argue that the duty to warn was particularly strong for this group.

Associated Injuries

Wegovy’s injury profile mirrors Ozempic’s, as both contain semaglutide:

• Gastroparesis — the most commonly alleged injury
• Gallbladder disease — including cholecystectomy
• Bowel obstruction
• Pancreatitis
• NAION (vision loss) — the Harvard JAMA Ophthalmology study included semaglutide users taking the drug for weight management. Learn more about Ozempic and NAION.

Litigation Status

Wegovy cases are consolidated with Ozempic cases in the MDL, as both involve the same active ingredient and manufacturer. Novo Nordisk faces claims for both products.

Trulicity (Dulaglutide) — Eli Lilly

What It Is

Trulicity is manufactured by Eli Lilly and was approved by the FDA in 2014 for type 2 diabetes. It contains dulaglutide, a GLP-1 receptor agonist administered as a once-weekly injection. Trulicity was one of the earlier GLP-1 drugs to achieve widespread use and has been prescribed to millions of patients.

Associated Injuries

Trulicity has been associated with the same class of gastrointestinal injuries as other GLP-1 drugs:

• Gastroparesis
• Bowel obstruction
• Gallbladder disease
• Pancreatitis
• Severe gastrointestinal events requiring hospitalization

Reports to the FDA Adverse Event Reporting System (FAERS) document numerous gastrointestinal adverse events associated with Trulicity dating back several years.

Litigation Status

Trulicity claims are part of the broader GLP-1 MDL. Because Trulicity has been on the market longer than Ozempic or Mounjaro, some Trulicity claimants may face statute of limitations considerations, though the discovery rule (which applies broadly to pharmaceutical claims) may protect claimants who were not aware of the drug’s role in their injuries.

Saxenda (Liraglutide) — Novo Nordisk

What It Is

Saxenda is manufactured by Novo Nordisk and was approved by the FDA in 2014 for chronic weight management. It contains liraglutide, a GLP-1 receptor agonist that is also sold under the brand name Victoza for type 2 diabetes. Saxenda requires daily injections, unlike the weekly dosing of newer GLP-1 drugs.

Associated Injuries

• Gastroparesis
• Gallbladder disease — the FDA has long required gallbladder-related warnings on Saxenda’s label
• Pancreatitis — Saxenda’s label includes warnings about acute pancreatitis
• Bowel obstruction

Litigation Status

Saxenda claims are included in the GLP-1 litigation. As an older GLP-1 drug with a well-documented side effect profile, Saxenda cases may involve additional allegations about the adequacy of existing warnings — specifically, whether the manufacturer provided sufficient warnings about the severity of gastrointestinal risks.

Rybelsus (Oral Semaglutide) — Novo Nordisk

What It Is

Rybelsus is Novo Nordisk’s oral formulation of semaglutide, approved by the FDA in 2019 for type 2 diabetes. It is the first and currently only oral GLP-1 receptor agonist, taken as a daily tablet rather than an injection.

Associated Injuries

Because Rybelsus contains semaglutide — the same active ingredient as Ozempic and Wegovy — its injury profile is consistent with the injectable formulations:

• Gastroparesis
• Gallbladder disease
• Bowel obstruction
• Pancreatitis

The oral delivery mechanism does not eliminate the gastrointestinal risks associated with semaglutide’s mechanism of action.

Litigation Status

Rybelsus claims are consolidated with other semaglutide cases in the MDL. Novo Nordisk faces allegations regarding all three of its semaglutide products.

What This Means for Your Claim

Regardless of which GLP-1 drug you took, the legal framework is the same:

1. You took a GLP-1 receptor agonist — any of the drugs listed above
2. You developed a qualifying injury — gastroparesis, bowel obstruction, gallbladder disease, pancreatitis, NAION, or other severe gastrointestinal injury
3. You have medical documentation — prescription records and diagnosis records
4. You are not already represented by another attorney in a GLP-1 claim

The MDL structure ensures that claims involving all GLP-1 drugs benefit from the same coordinated discovery process, expert development, and bellwether trial preparation. For a complete overview of which drugs qualify, see our eligibility guide.

Frequently Asked Questions

Do Mounjaro claims go through the same MDL as Ozempic claims?

Yes. MDL 3094 covers GLP-1 receptor agonist claims broadly, including claims against both Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda) and Eli Lilly (Mounjaro, Trulicity). All cases benefit from the coordinated pretrial process.

Is one GLP-1 drug worse than others for causing gastroparesis?

The clinical data does not clearly establish that one specific GLP-1 drug carries a dramatically higher gastroparesis risk than others. All GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action. Higher doses and longer duration of use may increase risk regardless of the specific drug.

I took multiple GLP-1 drugs. Does that affect my claim?

Taking multiple GLP-1 drugs does not disqualify you. In some cases, it may actually strengthen the causal narrative — prolonged exposure to drugs with the same mechanism of action may make the connection to your injury more apparent. Your attorney will evaluate the specifics.

What if the drug I took is no longer on the market?

Your legal rights are based on your exposure to the drug and your resulting injury, not on whether the drug is currently available. Even if a specific formulation is discontinued, the manufacturer remains liable for injuries caused during the period you used it.

Are there any GLP-1 drugs not covered by the litigation?

The MDL broadly covers GLP-1 receptor agonist claims. If you took a GLP-1 drug not listed here and developed a serious injury, consult with an attorney to determine whether your case fits within the litigation framework.

Take the Next Step

The GLP-1 litigation is not just about Ozempic. If you took Mounjaro, Wegovy, Trulicity, Saxenda, Rybelsus, or any other GLP-1 receptor agonist and suffered serious gastrointestinal injuries, vision loss, or other harm, you may have a viable legal claim.

If you or a loved one has been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629